全文获取类型
收费全文 | 436篇 |
免费 | 20篇 |
国内免费 | 9篇 |
专业分类
儿科学 | 20篇 |
妇产科学 | 5篇 |
基础医学 | 33篇 |
口腔科学 | 14篇 |
临床医学 | 49篇 |
内科学 | 118篇 |
皮肤病学 | 9篇 |
神经病学 | 9篇 |
特种医学 | 106篇 |
外科学 | 35篇 |
综合类 | 30篇 |
预防医学 | 11篇 |
眼科学 | 5篇 |
药学 | 2篇 |
肿瘤学 | 19篇 |
出版年
2023年 | 1篇 |
2021年 | 1篇 |
2020年 | 1篇 |
2019年 | 2篇 |
2018年 | 3篇 |
2017年 | 4篇 |
2016年 | 1篇 |
2015年 | 9篇 |
2014年 | 7篇 |
2013年 | 9篇 |
2011年 | 9篇 |
2010年 | 20篇 |
2009年 | 18篇 |
2008年 | 6篇 |
2007年 | 14篇 |
2006年 | 14篇 |
2005年 | 6篇 |
2004年 | 17篇 |
2003年 | 3篇 |
2002年 | 3篇 |
2001年 | 8篇 |
2000年 | 2篇 |
1999年 | 5篇 |
1998年 | 26篇 |
1997年 | 25篇 |
1996年 | 36篇 |
1995年 | 20篇 |
1994年 | 14篇 |
1993年 | 19篇 |
1992年 | 3篇 |
1991年 | 8篇 |
1990年 | 10篇 |
1989年 | 11篇 |
1988年 | 17篇 |
1987年 | 13篇 |
1986年 | 14篇 |
1985年 | 10篇 |
1984年 | 9篇 |
1983年 | 12篇 |
1982年 | 8篇 |
1981年 | 13篇 |
1980年 | 7篇 |
1979年 | 1篇 |
1978年 | 5篇 |
1977年 | 7篇 |
1976年 | 7篇 |
1975年 | 4篇 |
1973年 | 2篇 |
1972年 | 1篇 |
排序方式: 共有465条查询结果,搜索用时 937 毫秒
101.
102.
H. J. SCHINDLER J. LENZ J. C. TÜRP K. SCHWEIZERHOF & S. RUES 《Journal of oral rehabilitation》2009,36(10):710-718
Summary After complex prosthetic reconstructions, small differences in vertical distances between the left and right side of the jaw may occur during jaw closing, nevertheless providing bilateral tooth contacts in intercuspation by small deformations of the mandible. Their effects on the co-contraction of the masticatory muscles, the temporomandibular joint reaction forces, and the point of application of the resultant bite force vector in the maxillary occlusion plane – the so-called reduction point – have not been investigated, thus far simultaneously in one sample. The main goal of this study was to investigate variations of these measures in an experimental intercuspation simulated by one anterior and two posterior force transmission points. 相似文献
103.
104.
Rosenzweig M; Marks DF; Zhu H; Hempel D; Mansfield KG; Sehgal PK; Kalams S; Scadden DT; Johnson RP 《Blood》1996,87(10):4040-4048
105.
106.
Nonrandom association of free iron with membranes of sickle and beta- thalassemic erythrocytes 总被引:2,自引:2,他引:2
Repka T; Shalev O; Reddy R; Yuan J; Abrahamov A; Rachmilewitz EA; Low PS; Hebbel RP 《Blood》1993,82(10):3204-3210
To further define the nature of abnormal iron deposits on the membranes of pathologic red blood cells, we have used sickle cell anemia (HbSS), HbSC, and beta-thalassemic erythrocytes (RBCs) to prepare inside-out membranes (IOM) and insoluble membrane aggregates (AGGs) containing coclustered hemichrome and band 3. Study of IOM from HbSC and thalassemic patients showed that amounts of heme iron and, especially, free iron were much higher in patients who had undergone surgical splenectomy. The membrane AGGs from HbSS and beta-thalassemic RBCs contained much more globin than heme, with this discrepancy being variable from patient to patient. Although these AGGs were enriched (compared with the ghosts from which they were derived) for heme, as expected, less than 10% of total ghost heme was recovered in them. Remarkably, these AGGs also were enriched for nonheme iron, markedly so in some patients. Iron binding studies showed that the association of free iron with these hemichrome/band 3 AGGs is explained by the fact that free iron binds to denatured hemoglobin. These results document that free iron is nonrandomly associated with the membranes of sickle and beta-thalassemic RBCs. Whether this plays a causative role in the premature removal of such cells from the circulation remains to be seen. 相似文献
107.
108.
109.
Red blood cells (RBCs) from patients with sickle cell anemia and thalassemia carry abnormal accumulations of molecular Fe(III) at the cytosol/membrane interface. The avidity of the red cell membrane for this iron has not been defined. Using open ghost membranes prepared from sickle RBC, we examined the ability of membrane-associated Fe(III) to resist removal by 15 chelators representing a 40-log range of affinities for Fe(III). Efficacy of chelators was compared with literature values for their idealized affinity for iron as represented by the cummulative stability constant (beta n), their effective stability constant reflecting affinity under biologic conditions (Keff), and an indicator of their ability to chelate Fe(III) in the presence of an insoluble phase of iron (Ksol). Deferoxamine, a very high affinity chelator having log beta n = 30.6, was found to be the lowest affinity chelator able to remove RBC membrane Fe(III). Regardless of chelator beta n, only those agents able to preserve log Keff > or = 12 were able to do so, indicating that the membrane's effective avidity for Fe(III) is on the order of 10(12). Additional confirmation that membrane avidity for Fe(III) is extremely high is found in the observation that only chelators having log Ksol > 0 were effective. Potential physiologic iron chelators in cytoplasm of pathologic red cells are unable to prevent or reverse iron accumulation on the membrane because they do not have sufficiently high affinity for iron. These data argue that RBC membrane Fe(III) is truly pathologic. 相似文献
110.
Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo 总被引:3,自引:2,他引:3
Shalev O; Repka T; Goldfarb A; Grinberg L; Abrahamov A; Olivieri NF; Rachmilewitz EA; Hebbel RP 《Blood》1995,86(5):2008-2013
Red blood cell (RBC) membranes from patients with the thalassemic and sickle hemoglobinopathies carry abnormal deposits of iron presumed to mediate a variety of oxidative-induced membrane dysfunctions. We hypothesized that the oral iron chelator deferiprone (L1), which has an enhanced capacity to permeate cell membranes, might be useful in chelating these pathologic iron deposits from intact RBCs. We tested this hypothesis in vitro by incubating L1 with RBCs from 15 patients with thalassemia intermedia and 6 patients with sickle cell anemia. We found that removal of RBC membrane free iron by L1 increased both as a function of time of incubation and L1 concentration. Thus, increasing the time of incubation of thalassemic RBCs with 0.5 mmol/L L1 from 0.5 to 6 hours, enhanced removal of their membrane free iron from 18% +/- 9% to 96% +/- 4%. Dose-response studies showed that incubating thalassemic RBC for 2 hours with L1 concentrations ranging from 0.125 to 0.5 mmol/L resulted in removal of membrane free iron from 28% +/- 15% to 68% +/- 11%. Parallel studies with sickle RBCs showed a similar pattern in time and dose responses. Deferoxamine (DFO), on the other hand, was ineffective in chelating membrane free iron from either thalassemic or sickle RBCs regardless of dose (maximum, 0.333 mmol/L) or time of incubation (maximum, 24 hours). In vivo efficacy of L1 was shown in six thalassemic patients whose RBC membrane free iron decreased by 50% +/- 29% following a 2-week course of L1 at a daily dose of 25 mg/kg. As the dose of L1 was increased to 50 mg/kg/d (n = 5), and then to 75 mg/kg/d (n = 4), 67% +/- 14% and 79% +/- 11%, respectively, of their RBC membrane free iron was removed. L1 therapy-- both in vitro and in vivo--also significantly attenuated the malondialdehyde response of thalassemic RBC membranes to in vitro stimulation with peroxide. Remarkably, the heme content of RBC membranes from L1-treated thalassemic patients decreased by 28% +/- 10% during the 3-month study period. These results indicate that L1 can remove pathologic deposits of chelatable iron from thalassemic and sickle RBC membranes, a therapeutic potential not shared by DFO. Furthermore, membrane defects possibly mediated by catalytic iron, such as lipid peroxidation and hemichrome formation, may also be alleviated, at least in part, by L1. 相似文献